Filing Flows › Health Care › Staar Surgical (STAA)
Staar Surgical (STAA) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Staar Surgical (STAA) Q3 2026 earnings results →
Q3 2026 Revenue down 12% year over year to $83.4M · 7¢ of every $1 of revenue kept as net profit · operating margin 6.5%
Staar Surgical made $83.4M in Q3 2026 (-12% Y/Y). Operating margin 6.5%, net earnings $5.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $83.4M in Q3 2026, down 12% year over year and down 11% from the previous quarter.
Gross margin was 70.9%, down 11.3 points from Q3 2025. Operating profit was $5.5M, a 6.5% margin (down 13.0 points year over year). Operating expenses fell 10% while revenue fell 12%. Net earnings were $5.6M, down 37% year over year. The effective tax rate was 20.1%. Non-operating items added $1.5M, 22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $27.3M (up 924% year over year), 490% of net earnings. Non-cash charges added back $2.4M of depreciation and $5.5M of share-based compensation. Working capital and other items added $13.8M. After acquisition of property and equipment ($935K), free cash flow as the company reports it was $26.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $83.4M | -12% | 6.5% | $5.6M | $27.3M |
| Q2 2026 | 10-Q | Aug 12, 2026 | $93.5M | +111% | 10.8% | $8.1M | $19.7M |
| Q1 2026 | 10-Q | May 13, 2026 | $93.5M | +120% | 8.5% | $5.2M | −$21.7M |
| Q4 2025 | 10-K | Mar 3, 2026 | $57.8M | +18% | -39.5% | −$18.3M | −$3.9M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $94.7M | +7% | 19.5% | $8.9M | $2.7M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $44.3M | -55% | -67.6% | −$16.8M | −$27.2M |
| Q1 2025 | 10-Q | May 7, 2025 | $42.6M | -45% | -134.8% | −$54.2M | −$5.7M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Staar Surgical
STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure. STAAR has sold more than 4 million ICLs in over 85 countries.
In its own words, from its 8-K, filed Aug 12, 2026.
Staar Surgical against its Ophthalmic Goods peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -12% against the peers' median +2%. Operating margin: 6.5% against the peers' median 4.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| STAA Staar Surgical | Q3 2026 | $83.4M | -12% | 6.5% |
| BLCO Bausch & Lomb | Q3 2026 | $1.4B | +7% | 11.3% |
| COO Cooper Companies | Q3 FY26 | $1.1B | +0.6% | 20.8% |
| EYE National Vision Holdings | Q2 2026 | $499M | +2% | 4.3% |
| WRBY Warby Parker | Q3 2026 | $245M | +10% | 1.5% |
| RXST RxSight | Q3 2026 | $24.6M | -19% | -75.3% |
| LUCYW Innovative Eyewear | Q2 2026 | $1.0M | +74% | -165.3% |
Source: Staar Surgical 10-Q on SEC EDGAR · CIK 718937 · Ophthalmic Goods
Guidance and outlook
13F: who owns STAA and who is buying
More on STAA
- How Staar Surgical makes money: revenue by segment
- Staar Surgical next earnings date and what analysts expect
- Staar Surgical stock forecast, price target and fair value
- Who owns Staar Surgical stock: holders, funds and Congress trades
- Staar Surgical guidance and outlook
- Is Staar Surgical a takeover target? LBO and rumors
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results